Share-based Payment Arrangement, Expense of AMICUS THERAPEUTICS, INC. from 31 Dec 2010 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
AMICUS THERAPEUTICS, INC. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2010 to 30 Sep 2025.
  • AMICUS THERAPEUTICS, INC. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $18,089,000, a 3.2% decline year-over-year.
  • AMICUS THERAPEUTICS, INC. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $80,037,000, a 4.5% decline year-over-year.
  • AMICUS THERAPEUTICS, INC. annual Share-based Payment Arrangement, Expense for 2024 was $84,905,000, a 1.4% decline from 2023.
  • AMICUS THERAPEUTICS, INC. annual Share-based Payment Arrangement, Expense for 2023 was $86,077,000, a 13% increase from 2022.
  • AMICUS THERAPEUTICS, INC. annual Share-based Payment Arrangement, Expense for 2022 was $76,512,000, a 32% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

AMICUS THERAPEUTICS, INC. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $80,037,000 $18,089,000 -$599,000 -3.2% 01 Jul 2025 30 Sep 2025 10-Q 04 Nov 2025 2025 Q3
Q2 2025 $80,636,000 $17,559,000 +$1,362,000 +8.4% 01 Apr 2025 30 Jun 2025 10-Q 31 Jul 2025 2025 Q2
Q1 2025 $79,274,000 $25,172,000 -$5,631,000 -18% 01 Jan 2025 31 Mar 2025 10-Q 01 May 2025 2025 Q1
Q4 2024 $84,905,000 $19,217,000 +$1,122,000 +6.2% 01 Oct 2024 31 Dec 2024 10-K 19 Feb 2025 2024 FY
Q3 2024 $83,783,000 $18,688,000 +$2,177,000 +13% 01 Jul 2024 30 Sep 2024 10-Q 04 Nov 2025 2025 Q3
Q2 2024 $81,606,000 $16,197,000 -$380,000 -2.3% 01 Apr 2024 30 Jun 2024 10-Q 31 Jul 2025 2025 Q2
Q1 2024 $81,986,000 $30,803,000 -$4,091,000 -12% 01 Jan 2024 31 Mar 2024 10-Q 01 May 2025 2025 Q1
Q4 2023 $86,077,000 $18,095,000 -$531,000 -2.9% 01 Oct 2023 31 Dec 2023 10-K 19 Feb 2025 2024 FY
Q3 2023 $86,608,000 $16,511,000 +$1,739,000 +12% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024 2024 Q3
Q2 2023 $84,869,000 $16,577,000 +$4,114,000 +33% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $80,755,000 $34,894,000 +$4,243,000 +14% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $76,512,000 $18,626,000 +$4,719,000 +34% 01 Oct 2022 31 Dec 2022 10-K 19 Feb 2025 2024 FY
Q3 2022 $71,793,000 $14,772,000 +$2,931,000 +25% 01 Jul 2022 30 Sep 2022 10-Q 08 Nov 2023 2023 Q3
Q2 2022 $68,862,000 $12,463,000 +$727,000 +6.2% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $68,135,000 $30,651,000 +$10,297,000 +51% 01 Jan 2022 31 Mar 2022 10-Q 10 May 2023 2023 Q1
Q4 2021 $57,838,000 $13,907,000 +$1,668,000 +14% 01 Oct 2021 31 Dec 2021 10-K 28 Feb 2024 2023 FY
Q3 2021 $56,170,000 $11,841,000 -$4,067,000 -26% 01 Jul 2021 30 Sep 2021 10-Q 07 Nov 2022 2022 Q3
Q2 2021 $60,237,000 $11,736,000 +$3,328,000 +40% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $56,909,000 $20,354,000 +$7,758,000 +62% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q4 2020 $49,151,000 $12,239,000 -$669,000 -5.2% 01 Oct 2020 31 Dec 2020 10-K 01 Mar 2023 2022 FY
Q3 2020 $49,820,000 $15,908,000 +$7,065,000 +80% 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021 2021 Q3
Q2 2020 $42,755,000 $8,408,000 -$1,527,000 -15% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 $44,282,000 $12,596,000 -$148,000 -1.2% 01 Jan 2020 31 Mar 2020 10-Q 10 May 2021 2021 Q1
Q4 2019 $44,430,000 $12,908,000 +$4,521,000 +54% 01 Oct 2019 31 Dec 2019 10-K 24 Feb 2022 2021 FY
Q3 2019 $39,909,000 $8,843,000 +$1,789,000 +25% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $38,120,000 $9,935,000 +$3,594,000 +57% 01 Apr 2019 30 Jun 2019 10-Q 10 Aug 2020 2020 Q2
Q1 2019 $34,526,000 $12,744,000 +$5,266,000 +70% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q4 2018 $29,260,000 $8,387,000 +$2,353,000 +39% 01 Oct 2018 31 Dec 2018 10-K 01 Mar 2021 2020 FY
Q3 2018 $26,907,000 $7,054,000 +$1,554,000 +28% 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019 2019 Q3
Q2 2018 $25,353,000 $6,341,000 +$804,000 +15% 01 Apr 2018 30 Jun 2018 10-Q 08 Aug 2019 2019 Q2
Q1 2018 $24,549,000 $7,478,000 +$1,448,000 +24% 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019 2019 Q1
Q4 2017 $23,101,000 $6,034,000 +$1,617,000 +37% 01 Oct 2017 31 Dec 2017 10-K 02 Mar 2020 2019 FY
Q3 2017 $21,484,000 $5,500,000 +$1,162,000 +27% 01 Jul 2017 30 Sep 2017 10-Q 05 Nov 2018 2018 Q3
Q2 2017 $20,322,000 $5,537,000 +$1,071,000 +24% 01 Apr 2017 30 Jun 2017 10-Q 07 Aug 2018 2018 Q2
Q1 2017 $19,251,000 $6,030,000 +$1,747,000 +41% 01 Jan 2017 31 Mar 2017 10-Q 09 May 2018 2018 Q1
Q4 2016 $17,504,000 $4,417,000 +$1,373,000 +45% 01 Oct 2016 31 Dec 2016 10-K 28 Feb 2019 2018 FY
Q3 2016 $16,131,000 $4,338,000 +$1,601,000 +58% 01 Jul 2016 30 Sep 2016 10-Q 08 Nov 2017 2017 Q3
Q2 2016 $14,530,000 $4,466,000 +$2,235,000 +100% 01 Apr 2016 30 Jun 2016 10-Q 07 Aug 2017 2017 Q2
Q1 2016 $12,295,000 $4,283,000 +$2,323,000 +119% 01 Jan 2016 31 Mar 2016 10-Q 09 May 2017 2017 Q1
Q4 2015 $9,972,000 $3,044,000 +$1,437,000 +89% 01 Oct 2015 31 Dec 2015 10-K 01 Mar 2018 2017 FY
Q3 2015 $8,535,000 $2,737,000 +$1,086,000 +66% 01 Jul 2015 30 Sep 2015 10-Q 07 Nov 2016 2016 Q3
Q2 2015 $7,449,000 $2,231,000 +$741,000 +50% 01 Apr 2015 30 Jun 2015 10-Q 09 Aug 2016 2016 Q2
Q1 2015 $6,708,000 $1,960,000 +$700,000 +56% 01 Jan 2015 31 Mar 2015 10-Q 03 May 2016 2016 Q1
Q4 2014 $6,008,000 $1,607,000 +$104,000 +6.9% 01 Oct 2014 31 Dec 2014 10-K/A 03 Mar 2017 2016 FY
Q3 2014 $5,904,000 $1,651,000 +$134,000 +8.8% 01 Jul 2014 30 Sep 2014 10-Q 04 Nov 2015 2015 Q3
Q2 2014 $5,770,000 $1,490,000 -$93,000 -5.9% 01 Apr 2014 30 Jun 2014 10-Q 05 Aug 2015 2015 Q2
Q1 2014 $5,863,000 $1,260,000 -$314,000 -20% 01 Jan 2014 31 Mar 2014 10-Q 05 May 2015 2015 Q1
Q4 2013 $6,177,000 $1,503,000 +$55,000 +3.8% 01 Oct 2013 31 Dec 2013 10-K 29 Feb 2016 2015 FY
Q3 2013 $6,122,000 $1,517,000 -$81,000 -5.1% 01 Jul 2013 30 Sep 2013 10-Q 06 Nov 2014 2014 Q3
Q2 2013 $6,203,000 $1,583,000 -$174,000 -9.9% 01 Apr 2013 30 Jun 2013 10-Q 07 Aug 2014 2014 Q2
Q1 2013 $6,377,000 $1,574,000 +$186,000 +13% 01 Jan 2013 31 Mar 2013 10-Q 05 May 2014 2014 Q1
Q4 2012 $6,191,000 $1,448,000 01 Oct 2012 31 Dec 2012 10-K 03 Mar 2015 2014 FY
Q3 2012 $1,598,000 01 Jul 2012 30 Sep 2012 10-Q 12 Nov 2013 2013 Q3
Q2 2012 $1,757,000 01 Apr 2012 30 Jun 2012 10-Q 07 Aug 2013 2013 Q2
Q1 2012 $1,388,000 01 Jan 2012 31 Mar 2012 10-Q 09 May 2013 2013 Q1

AMICUS THERAPEUTICS, INC. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $84,905,000 -$1,172,000 -1.4% 01 Jan 2024 31 Dec 2024 10-K 19 Feb 2025 2024 FY
2023 $86,077,000 +$9,565,000 +13% 01 Jan 2023 31 Dec 2023 10-K 19 Feb 2025 2024 FY
2022 $76,512,000 +$18,674,000 +32% 01 Jan 2022 31 Dec 2022 10-K 19 Feb 2025 2024 FY
2021 $57,838,000 +$8,687,000 +18% 01 Jan 2021 31 Dec 2021 10-K 28 Feb 2024 2023 FY
2020 $49,151,000 +$4,721,000 +11% 01 Jan 2020 31 Dec 2020 10-K 01 Mar 2023 2022 FY
2019 $44,430,000 +$15,170,000 +52% 01 Jan 2019 31 Dec 2019 10-K 24 Feb 2022 2021 FY
2018 $29,260,000 +$6,159,000 +27% 01 Jan 2018 31 Dec 2018 10-K 01 Mar 2021 2020 FY
2017 $23,101,000 +$5,597,000 +32% 01 Jan 2017 31 Dec 2017 10-K 02 Mar 2020 2019 FY
2016 $17,504,000 +$7,532,000 +76% 01 Jan 2016 31 Dec 2016 10-K 28 Feb 2019 2018 FY
2015 $9,972,000 +$3,964,000 +66% 01 Jan 2015 31 Dec 2015 10-K 01 Mar 2018 2017 FY
2014 $6,008,000 -$169,000 -2.7% 01 Jan 2014 31 Dec 2014 10-K/A 03 Mar 2017 2016 FY
2013 $6,177,000 -$14,000 -0.23% 01 Jan 2013 31 Dec 2013 10-K 29 Feb 2016 2015 FY
2012 $6,191,000 -$2,488,000 -29% 01 Jan 2012 31 Dec 2012 10-K 03 Mar 2015 2014 FY
2011 $8,679,000 +$2,479,000 +40% 01 Jan 2011 31 Dec 2011 10-K 03 Mar 2014 2013 FY
2010 $6,200,000 01 Jan 2010 31 Dec 2010 10-K 13 Mar 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.